Adrian Elfersy, MD
Ophthalmology · Charlotte, NCNPI 1457670606
Payments from drug & device makers
Across 329 payments — averaging $38.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$10K
- AbbVie$1K
- Johnson & Johnson Surgical Vision, Inc.$370
- Aerie Pharmaceuticals, Inc.$299
- NEW World Medical,inc.$215
- Amgen$192
- plus $612 from 13 others
What the payments were for
- Food & beverage$12,519100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 195 | $9,578 |
| AbbVie(2 entities) | 69 | $1,254 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $370 |
| Aerie Pharmaceuticals, Inc. | 14 | $299 |
| NEW World Medical,inc. | 7 | $215 |
| Amgen(2 entities) | 9 | $192 |
| Sun Pharmaceutical Industries Inc. | 8 | $155 |
| Tarsus Pharmaceuticals, Inc. | 3 | $108 |
| Sight Sciences, Inc. | 5 | $88 |
| Bausch & Lomb Americas Inc. | 3 | $51 |
| Dompe US, Inc. | 2 | $38 |
| Novartis | 2 | $35 |
| Kala Pharmaceuticals, Inc. | 2 | $32 |
| Glaukos Corporation | 1 | $26 |
| Iridex Corporation | 1 | $19 |
| Optinose US, Inc. | 1 | $17 |
| Biotissue Holdings Inc. | 1 | $16 |
| Eyevance Pharmaceuticals LLC | 1 | $15 |
| Eyepoint US, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$1,420
- LenSx$673
- Hydrus Microstent$514
- Unity$376
- AcrySof IQ VIVITY IOL$289
- PanOptix$264
- XEN GLAUCOMA TREATMENT SYSTEM$230
- VUITY$132
- XEN$125
- Tecnis Toric 1-piece IOL$124
- Tecnis Multifocal Family of 1-piece IOLS$124
- Tecnis iTec Preloaded Delivery System$124
- Catalys Laser System$124
- AcrySof IQ PanOptix$121
- Ahmed Glaucoma Valve$119
- Kahook Dual Blade$119
- Tecnis Symfony IOL$118
- Tecnis Simplicity$114
- Rhopressa$113
- Rocklatan$113
How this compares
$12,519 in reported general payments places this provider in the 85th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 255 | $113,738 |
| RocklatanNetarsudil Mesylat/Latanoprost | 174 | $76,659 |
| CombiganBrimonidine Tartrate/Timolol | 189 | $59,529 |
| RestasisCyclosporine | 73 | $58,357 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 151 | $24,578 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 80 | $19,038 |
| Latanoprost | 1,952 | $16,933 |
| VyzultaLatanoprostene Bunod | 34 | $16,482 |
| Cyclosporine | 24 | $15,628 |
| XiidraLifitegrast | 14 | $10,756 |
| Alphagan PBrimonidine Tartrate | 38 | $10,738 |
| Travoprost | 52 | $8,457 |
| RhopressaNetarsudil Mesylate | 17 | $7,768 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 451 | $6,549 |
| Brimonidine Tartrate | 269 | $6,281 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $1,254 | $242,363555 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $299 | $84,427191 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $51 | $27,23748 claims |
| AlconSimbrinza | $9,578 | $19,03880 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 588 ophthalmology providers in North Carolina.
Other ophthalmology in Charlotte
- Andrew AntoszykCharlotte$4M
- Omar PunjabiCharlotte$413K
- Thomas MundorfCharlotte$288K
- John AllenCharlotte$122K
- Sheila Garcia-SantanaCharlotte$60K
- David BrowningCharlotte$59K
- Glenn JaffeDurham$38.5M
- Lejla VajzovicDurham$7.5M
- Majda HadziahmetovicDurham$2.4M
- Preeya GuptaRaleigh$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.